{"PubmedArticle": [{"MedlineCitation": {"OtherID": [], "SpaceFlightMission": [], "KeywordList": [["COVID-19 lethality", "COVID-19 treatment", "SARS-CoV-2 epidemiology", "healthcare system", "outpatient care", "paracetamol", "treatment guidelines"]], "CitationSubset": [], "InvestigatorList": [], "OtherAbstract": [], "GeneralNote": [], "PMID": "37168835", "DateRevised": {"Year": "2023", "Month": "05", "Day": "16"}, "Article": {"Language": ["eng"], "ArticleDate": [], "ELocationID": ["10.26502/fjppr.055"], "Journal": {"ISSN": "2578-1553", "JournalIssue": {"Volume": "6", "Issue": "3", "PubDate": {"Year": "2022", "Month": "Aug", "Day": "02"}}, "Title": "Journal of pharmacy and pharmacology research", "ISOAbbreviation": "J Pharm Pharmacol Res"}, "ArticleTitle": "The Problem of Home Therapy during COVID-19 Pandemic in Italy: Government Guidelines versus Freedom of Cure?", "Pagination": {"StartPage": "100", "EndPage": "114", "MedlinePgn": "100-114"}, "Abstract": {"AbstractText": ["After starting in late 2019, COVID-19 spread worldwide, and Italy was one of the first Western nations to be seriously affected. At that time, both the virus and the disease were little known and there were no Evidence-Based Medicine indications for treatment. The Italian Health Ministry guidelines claimed that, unless oxygen saturation fell to <92%, no pharmacological treatment was necessary during the first 72 hours, other than on a purely symptomatic basis, preferably with paracetamol. As later confirmed, that delay in therapeutic intervention may have been responsible for numerous hospital admissions and a very high lethality (3.5 %). To try to remedy this situation, several volunteer groups were formed, managing to promptlycure thousands of patients at home with non-steroidal anti-inflammatory drugs and a variety of re-purposed drugs (principally hydroxychloroquine, ivermectin) and supplements (such as antioxidants, polyphenols and vitamin D). Although not documented by any randomized controlled studies, these approaches were nonetheless based on the best available evidence, were aimed at addressing otherwise unmet major needs and produced a significant reduction of hospitalizations, of symptom duration, and a complete recovery from the disease compared with late treatment, according to some retrospective observational studies and the clinical experience of many physicians. A prompt discussion, with a clear and open exchange between healthcare Institutions and the said groups of voluntary physicians, could clarify the most effective approaches to reduce the number of hospitalizations and the lethality of this disease."]}, "AuthorList": [{"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medical School University Federico II, Naples (retired professor), Italy."}], "LastName": "Fazio", "ForeName": "Serafino", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center of Research in Medical Pharmacology, University of Insubria, Varese, Italy."}], "LastName": "Cosentino", "ForeName": "Marco", "Initials": "M"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Center of Research in Medical Pharmacology, University of Insubria, Varese, Italy."}], "LastName": "Marino", "ForeName": "Franca", "Initials": "F"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "High School Master of Oxygen-Ozone Therapy, University of Pavia, Italy."}], "LastName": "Pandolfi", "ForeName": "Sergio", "Initials": "S"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Department of Diagnostics and Public Health, University of Verona, Italy."}], "LastName": "Zanolin", "ForeName": "Elisabetta", "Initials": "E"}, {"Identifier": [], "AffiliationInfo": [{"Identifier": [], "Affiliation": "Medical School University of Verona, Verona (retired professor), Italy."}], "LastName": "Bellavite", "ForeName": "Paolo", "Initials": "P"}], "GrantList": [{"GrantID": "R01 HL144125", "Acronym": "HL", "Agency": "NHLBI NIH HHS", "Country": "United States"}], "PublicationTypeList": ["Journal Article"]}, "MedlineJournalInfo": {"Country": "United States", "MedlineTA": "J Pharm Pharmacol Res", "NlmUniqueID": "9918419159206676", "ISSNLinking": "2578-1553"}, "CoiStatement": "Potential Conflicts of interest: P.B. has a consultancy agreement with Vanda s.r.l. (Frascati, Rome). The other authors have no competing interests to declare."}, "PubmedData": {"ReferenceList": [{"Reference": [{"Citation": "Scotto Di Vetta M, Morrone M, Fazio S. COVID-19: Off-label therapies based on mechanism of action while waiting for evidence-based medicine recommendations. World J Meta-Anal 8 (2020): 173\u2013177."}, {"Citation": "Amici C, Di CA, Ciucci A, Chiappa L, Castilletti C, Martella V, et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir Ther 11 (2006): 1021\u20131030.", "ArticleIdList": ["17302372"]}, {"Citation": "Rezza GU, Urbani A. Circolare recante \u201cGestione domiciliare dei pazienti con infezione da SARS-CoV-2\u201d. in (Sanitaria DGdPSedP, ed), Ministero della Salute, Roma: (2020)."}, {"Citation": "Fabiani M, Puopolo M, Morciano C, Spuri M, Spila Alegiani S, Filia A, et al. Effectiveness of mRNA vaccines and waning of protection against SARS-CoV-2 infection and severe covid-19 during predominant circulation of the delta variant in Italy: retrospective cohort study. BMJ 376 (2022): e069052.", "ArticleIdList": ["PMC8829820", "35144968"]}, {"Citation": "Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study. Lancet 399 (2022): 1303\u20131312.", "ArticleIdList": ["PMC8926413", "35305296"]}, {"Citation": "Nordstrom P, Ballin M, Nordstrom A. Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden. Lancet Infect Dis 22 (2022): 781\u2013790.", "ArticleIdList": ["PMC8971363", "35366962"]}, {"Citation": "Fazio S, Bellavite P, Zanolin E, McCullough PA, Pandolfi S, Affuso F. Retrospective Study of Outcomes and Hospitalization Rates of Patients in Italy with a Confirmed Diagnosis of Early COVID-19 and Treated at Home Within 3 Days or After 3 Days of Symptom Onset with Prescribed and Non-Prescribed Treatments Between November 2020 and August 2021. Med Sci Monit 27 (2021): e935379.", "ArticleIdList": ["PMC8725339", "34966165"]}, {"Citation": "Cosentino M, Vernocchi V, Martini S, Marino F, Allasino B, Balzola M, et al. Early outpatient treatment of COVID-19: a retrospective analysis of 392 cases in Italy MedXriv (2022).", "ArticleIdList": ["PMC9605012", "36294461"]}, {"Citation": "D\u2019Amario CR, Rossi P. Indicazioni emergenziali connesse ad epidemia COVID-19 riguardanti il settore funebre, cimiteriale e di cremazione in (Sanitaria DGdP, ed), Ministero della Salute, Roma: (2020)."}, {"Citation": "Wichmann D, Sperhake JP, Lutgehetmann M, Steurer S, Edler C, Heinemann A, et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med 173 (2020): 268\u2013277.", "ArticleIdList": ["PMC7240772", "32374815"]}, {"Citation": "Rezza G Indicazioni emergenziali connesse ad epidemia SARS-CoV-2 riguardanti il settore funebre, cimiteriali e della cremazione - Versione 11 gennaio 2021 in (sanitaria Dgdp, ed), Ministero della Salute, Roma: (2021)."}, {"Citation": "Pandolfi S, Valdenassi L, Bjorklund G, Chirumbolo S, Lysiuk R, Lenchyk L, et al. COVID-19 Medical and Pharmacological Management in the European Countries Compared to Italy: An Overview. Int J Environ Res Public Health 19 (2022).", "ArticleIdList": ["PMC8998583", "35409942"]}, {"Citation": "Pandolfi S, Chirumbolo S, Ricevuti G, Valdenassi L, Bjorklund G, Lysiuk R, et al. Home pharmacological therapy in early COVID-19 to prevent hospitalization and reduce mortality: Time for a suitable proposal. Basic Clin Pharmacol Toxicol 130 (2022): 225\u2013239.", "ArticleIdList": ["PMC9011697", "34811895"]}, {"Citation": "Thomas SJ, Moreira ED Jr, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med 385 (2021): 1761\u20131773.", "ArticleIdList": ["PMC8461570", "34525277"]}, {"Citation": "Rohban T BNT162b2 Vaccine Booster and Covid-19 Mortality. N Engl J Med 386 (2022): 1000.", "ArticleIdList": ["35139266"]}, {"Citation": "Ma Q, Liu J, Liu Q, Kang L, Liu R, Jing W, et al. Global Percentage of Asymptomatic SARS-CoV-2 Infections Among the Tested Population and Individuals With Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis. JAMA Netw Open 4 (2021): e2137257.", "ArticleIdList": ["PMC8672238", "34905008"]}, {"Citation": "Suter F, Consolaro E, Pedroni S, Moroni C, Pasto E, Paganini MV, et al. A simple, home-therapy algorithm to prevent hospitalisation for COVID-19 patients: A retrospective observational matched-cohort study. EClinicalMedicine 37 (2021): 100941.", "ArticleIdList": ["PMC8189543", "34127959"]}, {"Citation": "Consolaro E, Suter F, Rubis N, Pedroni S, Moroni C, Pasto E, et al. A Home-Treatment Algorithm Based on Anti-inflammatory Drugs to Prevent Hospitalization of Patients With Early COVID-19: A Matched-Cohort Study (COVER 2). Front Med (Lausanne) 9 (2022): 785785.", "ArticleIdList": ["PMC9073076", "35530041"]}, {"Citation": "Lin WT, Hung SH, Lai CC, Wang CY, Chen CH. The impact of neutralizing monoclonal antibodies on the outcomes of COVID-19 outpatients: A systematic review and meta-analysis of randomized controlled trials. J Med Virol (2022).", "ArticleIdList": ["PMC9015482", "35088444"]}, {"Citation": "Vegivinti CTR, Evanson KW, Lyons H, Akosman I, Barrett A, Hardy N, et al. Efficacy of antiviral therapies for COVID-19: a systematic review of randomized controlled trials. BMC Infect Dis 22 (2022): 107.", "ArticleIdList": ["PMC8802260", "35100985"]}, {"Citation": "Okoli GN, Rabbani R, Al-Juboori A, Copstein L, Askin N, Abou-Setta AM. Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis. Expert Rev Anti Infect Ther 20 (2022): 267\u2013278.", "ArticleIdList": ["PMC8477589", "34323632"]}, {"Citation": "Kow CS, Ramachandram DS, Hasan SS. The use of neutralizing monoclonal antibodies and risk of hospital admission and mortality in patients with COVID-19: a systematic review and meta-analysis of randomized trials. Immunopharmacol Immunotoxicol 44 (2022): 28\u201334.", "ArticleIdList": ["PMC8607536", "34762561"]}, {"Citation": "Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med 383 (2020): 2451\u20132460.", "ArticleIdList": ["32412710"]}, {"Citation": "Marconi F Gestire la pandemia: linee guida e assistenza domiciliare al vaglio della giurisprudenza amministrativa. Il Diritto Amministrativo - Rivista Giuridica 5 (2022)."}, {"Citation": "Rezza GUA. Circolare recante \u201cGestione domiciliare dei pazienti con infezione da SARS-CoV-2\u201d aggiornata al 26 aprile 2021 in (Sanitaria DGdPSedP, ed), Ministero della Salute; Roma: (2021)."}, {"Citation": "Rezza GU, Urbani A. Circolare recante \u201cGestione domiciliare dei pazienti con infezione da SARS-CoV-2\u201d aggiornamento del 10 febbraio 2022 in (sanitaria Dgdpsedp, ed), Ministero della Salute, Roma: (2022)."}, {"Citation": "Cordon-Cardo C, Pujadas E, Wajnberg A, Sebra R, Patel G, Firpo-Betancourt A, et al. COVID-19: Staging of a New Disease. Cancer Cell 38 (2020): 594\u2013597.", "ArticleIdList": ["PMC7547574", "33086031"]}, {"Citation": "Turk C, Turk S, Malkan UY, Haznedaroglu IC. Three critical clinicobiological phases of the human SARS-associated coronavirus infections. Eur Rev Med Pharmacol Sci 24 (2020): 8606\u20138620.", "ArticleIdList": ["32894568"]}, {"Citation": "Alexander PE, Armstrong R, Fareed G, Lotus J, Oskoui R, Prodromos C, et al. Early multidrug treatment of SARS-CoV-2 infection (COVID-19) and reduced mortality among nursing home (or outpatient/ambulatory) residents. Med Hypotheses 153 (2021): 110622.", "ArticleIdList": ["PMC8178530", "34130113"]}, {"Citation": "McCullough PA, Alexander PE, Armstrong R, Arvinte C, Bain AF, Bartlett RP, et al. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Rev Cardiovasc Med 21 (2020): 517\u2013530.", "ArticleIdList": ["33387997"]}, {"Citation": "Ravichandran R, Mohan SK, Sukumaran SK Kamaraj D, Daivasuga SS, Ravi S, et al. An open label randomized clinical trial of Indomethacin for mild and moderate hospitalised Covid-19 patients. Sci Rep 12 (2022): 6413.", "ArticleIdList": ["PMC9016692", "35440611"]}, {"Citation": "Shekhar N, Kaur H, Sarma P, Prakash A, Medhi B. Indomethacin: an exploratory study of antiviral mechanism and host-pathogen interaction in COVID-19. Expert Rev Anti Infect Ther (2021).", "ArticleIdList": ["PMC8544661", "34633277"]}, {"Citation": "Desantis J, Mercorelli B, Celegato M, Croci F, Bazzacco A, Baroni M et al. Indomethacin-based PROTACs as pan-coronavirus antiviral agents. Eur J Med Chem 226 (2021): 113814.", "ArticleIdList": ["PMC8416298", "34534839"]}, {"Citation": "Fazio S, Affuso F, Bellavite P. A Review of the Potential Roles of Antioxidant and Anti-Inflammatory Pharmacological Approaches for the Management of Mild-to-Moderate Symptomatic COVID-19. Med Sci Monit 28 (2022): e936292.", "ArticleIdList": ["PMC8917781", "35256581"]}, {"Citation": "Sestili P, Fimognari C. Paracetamol-Induced Glutathione Consumption: Is There a Link With Severe COVID-19 Illness? Front Pharmacol 11 (2020): 579944.", "ArticleIdList": ["PMC7577213", "33117175"]}, {"Citation": "Rushworth GF, Megson IL. Existing and potential therapeutic uses for N-acetylcysteine: the need for conversion to intracellular glutathione for antioxidant benefits. Pharmacol Ther 141 (2014): 150\u2013159.", "ArticleIdList": ["24080471"]}, {"Citation": "De Flora S, Balansky R, La MS. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J 34 (2020): 13185\u201313193.", "ArticleIdList": ["PMC7436914", "32780893"]}, {"Citation": "Bellavite P Reappraisal of Dietary Phytochemicals for Coronavirus Infection: Focus on Hesperidin and Quercetin in Antioxidants (Waisundara VY, ed) (2021) 473\u2013487.", "ArticleIdList": ["0"]}, {"Citation": "Zhang X, Wu X, Hu Q, Wu J, Wang G, Hong Z, et al. Mitochondrial DNA in liver inflammation and oxidative stress. Life Sci 236 (2019): 116464.", "ArticleIdList": ["31078546"]}, {"Citation": "Bhargava A, Raghuram GV, Pathak N, Varshney S, Jatawa SK, Jain D, et al. Occult hepatitis C virus elicits mitochondrial oxidative stress in lymphocytes and triggers PI3-kinase-mediated DNA damage response. Free Radic Biol Med 51 (2011): 1806\u20131814.", "ArticleIdList": ["21893189"]}, {"Citation": "Kido H, Indalao IL, Kim H, Kimoto T, Sakai S, Takahashi E. Energy metabolic disorder is a major risk factor in severe influenza virus infection: Proposals for new therapeutic options based on animal model experiments. Respir Investig 54 (2016): 312\u2013319.", "ArticleIdList": ["27566378"]}, {"Citation": "Saleh J, Peyssonnaux C, Singh KK, Edeas M. Mitochondria and microbiota dysfunction in COVID-19 pathogenesis. Mitochondrion 54 (2020): 1\u20137.", "ArticleIdList": ["PMC7837003", "32574708"]}, {"Citation": "Suhail S, Zajac J, Fossum C, Lowater H, McCracken C, Severson N, et al. Role of Oxidative Stress on SARS-CoV (SARS) and SARS-CoV-2 (COVID-19) Infection: A Review. Protein J (2020).", "ArticleIdList": ["PMC7587547", "33106987"]}, {"Citation": "Keles ES. Mild SARS-CoV-2 infections in children might be based on evolutionary biology and linked with host reactive oxidative stress and antioxidant capabilities. New Microbes New Infect 36 (2020): 100723.", "ArticleIdList": ["PMC7313508", "32670592"]}, {"Citation": "Delgado-Roche L, Mesta F. Oxidative Stress as Key Player in Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection. Arch Med Res 51 (2020): 384\u2013387.", "ArticleIdList": ["PMC7190501", "32402576"]}, {"Citation": "Trujillo JA, Croft NP, Dudek NL, Channappanavar R, Theodossis A, Webb AI, et al. The cellular redox environment alters antigen presentation. J Biol Chem 289 (2014): 27979\u201327991.", "ArticleIdList": ["PMC4183829", "25135637"]}, {"Citation": "Hati S, Bhattacharyya S. Impact of Thiol-Disulfide Balance on the Binding of Covid-19 Spike Protein with Angiotensin-Converting Enzyme 2 Receptor. ACS Omega 5 (2020): 16292\u201316298.", "ArticleIdList": ["PMC7346263", "32656452"]}, {"Citation": "Dalan R, Bornstein SR, El-Armouche A, Rodionov RN, Markov A, Wielockx B, et al. The ACE-2 in COVID-19: Foe or Friend? Horm Metab Res 52 (2020): 257\u2013263.", "ArticleIdList": ["PMC7339082", "32340044"]}, {"Citation": "Roberts E, Delgado Nunes V, Buckner S, Latchem S, Constanti M, Miller P, et al. Paracetamol: not as safe as we thought? A systematic literature review of observational studies. Ann Rheum Dis 75 (2016): 552\u20139.", "ArticleIdList": ["PMC4789700", "25732175"]}, {"Citation": "Yadav DK, Singh A, Zhang Q, Bai X, Zhang W, Yadav RK, et al. Involvement of liver in COVID-19: systematic review and meta-analysis. Gut 70 (2021): 807\u2013809.", "ArticleIdList": ["PMC7948176", "32669289"]}, {"Citation": "Marin-Duenas I, Vega J, Carrillo-Ng H, Veramendi-Schult I, Zavaleta-Alva R, Vasquez-Elera L, et al. Alteration in liver function tests among patients hospitalized for COVID-19: a multicentric study in Peru. Rev Gastroenterol Peru 41 (2021): 86\u201393.", "ArticleIdList": ["34724689"]}, {"Citation": "Santus P, Corsico A, Solidoro P, Braido F, Di MF, Scichilone N. Oxidative stress and respiratory system: pharmacological and clinical reappraisal of N-acetylcysteine. COPD 11 (2014): 705\u2013717.", "ArticleIdList": ["PMC4245155", "24787454"]}, {"Citation": "De FS, Grassi C, Carati L. Attenuation of influenza-like symptomatology and improvement of cell-mediated immunity with long-term N-acetylcysteine treatment. Eur Respir J 10 (1997): 1535\u20131541.", "ArticleIdList": ["9230243"]}, {"Citation": "Soltan-Sharifi MS, Mojtahedzadeh M, Najafi A, Reza KM, Reza RM, Moradi M, et al. Improvement by N-acetylcysteine of acute respiratory distress syndrome through increasing intracellular glutathione, and extracellular thiol molecules and anti-oxidant power: evidence for underlying toxicological mechanisms. Hum Exp Toxicol 26 (2007): 697\u2013703.", "ArticleIdList": ["17984140"]}, {"Citation": "Poe FL, Corn J. N-Acetylcysteine: A potential therapeutic agent for SARS-CoV-2. Med Hypotheses 143 (2020): 109862.", "ArticleIdList": ["PMC7261085", "32504923"]}, {"Citation": "Andreou A, Trantza S, Filippou D, Sipsas N, Tsiodras S. COVID-19: The Potential Role of Copper and N-acetylcysteine (NAC) in a Combination of Candidate Antiviral Treatments Against SARS-CoV-2. In Vivo 34 (2020): 1567\u20131588.", "ArticleIdList": ["PMC8378025", "32503814"]}, {"Citation": "Zhou N, Yang X, Huang A, Chen Z. The potential mechanism of N-acetylcysteine in treating COVID-19. Curr Pharm Biotechnol (2020).", "ArticleIdList": ["33371832"]}, {"Citation": "Luo P, Liu Y, Liu D, Li J. Perspectives for the use of N-acetylcysteine as a candidate drug to treat COVID-19. Mini Rev Med Chem (2020).", "ArticleIdList": ["33109047"]}, {"Citation": "Ibrahim H, Perl A, Smith D, Lewis T, Kon Z, Goldenberg R, et al. Therapeutic blockade of inflammation in severe COVID-19 infection with intravenous N-acetylcysteine. Clin Immunol 219 (2020): 108544.", "ArticleIdList": ["PMC7374140", "32707089"]}, {"Citation": "Shi Z, Puyo CA N-Acetylcysteine to Combat COVID-19: An Evidence Review. Ther Clin Risk Manag 16 (2020): 1047\u20131055.", "ArticleIdList": ["PMC7649937", "33177829"]}, {"Citation": "de Alencar JCG, Moreira CL, M\u00c3\u00bcller AD, Chaves CE, Fukuhara MA, da Silva EA, et al. Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19. Clin Infect Dis (2020): 5910353.", "ArticleIdList": ["PMC7543361", "32964918"]}, {"Citation": "Carothers C, Birrer K, Vo M. Acetylcysteine for the Treatment of Suspected Remdesivir-Associated Acute Liver Failure in COVID-19: A Case Series. Pharmacotherapy 40 (2020): 1166\u20131171.", "ArticleIdList": ["PMC7537093", "33006138"]}, {"Citation": "Sackett DL, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn\u2019t. BMJ 312 (1996): 71\u20132.", "ArticleIdList": ["PMC2349778", "8555924"]}, {"Citation": "Allegri PMM A, Gulisano P, Burigana F, Ortolani R, Donzelli A, Valsecchi M, et al. La gestione dei pazienti COVID-19 in ambito domiciliare. Indirizzi operativi proposti dal gruppo di lavoro promosso da Luca Coletto, Capo Dipartimento Sanit\u00e0 Lega-Salvini premier in Documento depositato al Senato (Bagnai LCaA, ed), Atti parlamentari; Roma: (2021)."}, {"Citation": "Ravichandran R PP, Vijayaragavan S, Kalavakollu RT, Gaidhane S, Kumar RK. Efficacy and safety of indomethacin in COVID-19 patients. MedRxiv (2020)."}, {"Citation": "Zhou Q, Zhao S, Gan L, Wang Z, Peng S, Li Q, et al. Use of non-steroidal anti-inflammatory drugs and adverse outcomes during the COVID-19 pandemic: A systematic review and meta-analysis. EClinicalMedicine 46 (2022): 101373.", "ArticleIdList": ["PMC8989274", "35434582"]}, {"Citation": "Bellavite P, Donzelli A. Hesperidin and SARS-CoV-2: New Light on the Healthy Function of Citrus Fruits. Antioxidants (Basel) 9 (2020).", "ArticleIdList": ["PMC7465267", "32823497"]}, {"Citation": "Ricordi C, Pacifici F, Lanzoni G, Palamara AT, Garaci E, Della-Morte D. Dietary and Protective Factors to Halt or Mitigate Progression of Autoimmunity, COVID-19 and Its Associated Metabolic Diseases. Int J Mol Sci 22 (2021).", "ArticleIdList": ["PMC8003583", "33808574"]}, {"Citation": "Rizzuti B; Grande F; Conforti F; Jimenez-Alesanco A; Ceballos-Laita L; Ortega-Alarcon D, et al. Rutin Is a Low Micromolar Inhibitor of SARS-CoV-2 Main Protease 3CLpro: Implications for Drug Design of Quercetin Analogs. Biomedicines 9 (2021).", "ArticleIdList": ["PMC8066963", "33918402"]}, {"Citation": "Colunga Biancatelli RML, Berrill M, Catravas JD, Marik PE. Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19). Front Immunol 11 (2020): 1451.", "ArticleIdList": ["PMC7318306", "32636851"]}, {"Citation": "El-Missiry MA, El-Missiry ZM, Othman AI. Melatonin is a potential adjuvant to improve clinical outcomes in individuals with obesity and diabetes with coexistence of Covid-19. Eur J Pharmacol 882 (2020): 173329.", "ArticleIdList": ["PMC7324339", "32615182"]}, {"Citation": "Rondanelli M, Perna S, Gasparri C, Petrangolini G, Allegrini P, Cavioni A, et al. Promising Effects of 3-Month Period of Quercetin Phytosome((R)) Supplementation in the Prevention of Symptomatic COVID-19 Disease in Healthcare Workers: A Pilot Study. Life (Basel) 12 (2022).", "ArticleIdList": ["PMC8780248", "35054459"]}, {"Citation": "Pawar A, Russo M, Rani I, Goswami K, Russo GL, Pal A. A critical evaluation of risk to reward ratio of quercetin supplementation for COVID-19 and associated comorbid conditions. Phytother Res (2022).", "ArticleIdList": ["PMC9111035", "35393674"]}, {"Citation": "Shohan M, Nashibi R, Mahmoudian-Sani MR, Abolnezhadian F, Ghafourian M, Alavi SM, et al. The therapeutic efficacy of quercetin in combination with antiviral drugs in hospitalized COVID-19 patients: A randomized controlled trial. Eur J Pharmacol 914 (2022): 174615.", "ArticleIdList": ["PMC8638148", "34863994"]}, {"Citation": "Di Pierro F, Iqtadar S, Khan A, Ullah Mumtaz S, Masud Chaudhry M, Bertuccioli A, et al. Potential Clinical Benefits of Quercetin in the Early Stage of COVID-19: Results of a Second, Pilot, Randomized, Controlled and Open-Label Clinical Trial. Int J Gen Med 14 (2021): 2807\u20132816.", "ArticleIdList": ["PMC8238537", "34194240"]}, {"Citation": "Di Pierro F, Derosa G, Maffioli P, Bertuccioli A, Togni S, Riva A, et al. Possible Therapeutic Effects of Adjuvant Quercetin Supplementation Against Early-Stage COVID-19 Infection: A Prospective, Randomized, Controlled, and Open-Label Study. Int J Gen Med 14 (2021): 2359\u20132366.", "ArticleIdList": ["PMC8197660", "34135619"]}], "ReferenceList": []}], "History": [{"Year": "2023", "Month": "5", "Day": "12", "Hour": "1", "Minute": "8"}, {"Year": "2023", "Month": "5", "Day": "12", "Hour": "1", "Minute": "7"}, {"Year": "2023", "Month": "5", "Day": "11", "Hour": "19", "Minute": "28"}, {"Year": "2023", "Month": "5", "Day": "9"}], "PublicationStatus": "ppublish", "ArticleIdList": ["37168835", "NIHMS1884256", "PMC10167757", "10.26502/fjppr.055"]}}], "PubmedBookArticle": []}